Bicara Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-157.32	-137.95	-68	-51.99	-37.85
Depreciation & Amortization	0.13	0.11	0.06	0.02	0.01
Stock-Based Compensation	17.41	15.01	7.4	1.9	0.81
Other Adjustments	1.64	1.2	-0.08	14.06	-
Changes in Accounts Payable	19.67	10.46	2.64	-8.66	5.87
Changes in Other Operating Activities	2.2	4.35	-16.77	-0.96	-0.92
Operating Cash Flow	-116.24	-106.83	-74.75	-45.63	-32.08
Capital Expenditures	-0.34	-0.28	-0.07	-0.59	-0.19
Sale of Property, Plant & Equipment	-	-	0.06	-	-
Purchases of Investments	-82.09	-318.17	-	-	-
Proceeds from Sale of Investments	101	-	-	-	-
Investing Cash Flow	-217.51	-318.45	-0.01	-0.59	-0.19
Issuance of Common Stock	195.15	32.26	334.03	0.15	0.16
Net Common Stock Issued (Repurchased)	195.15	32.26	334.03	0.15	0.16
Issuance of Preferred Stock	-	-	-	272.35	31.54
Net Preferred Stock Issued (Repurchased)	-	-	-	272.35	31.54
Financing Cash Flow	195.15	32.26	334.03	272.5	31.7
Net Cash Flow	-138.6	-393.03	259.27	226.28	-0.57
Free Cash Flow	-116.58	-107.11	-74.82	-46.21	-32.27
Free Cash Flow Per Share	-2.07	-1.96	-4.45	-79.66	-75.20
Levered Free Cash Flow	-135.66	-123.32	-82.14	-62.18	-33.08
Unlevered Free Cash Flow	-152.62	-141.22	-96.76	-50.08	-32.89

Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q